The association between hypertension and nonalcoholic fatty liver disease (NAFLD): literature evidence and systems biology analysis

References

• Zhou F, Zhou J, Wang W, et al. Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: a Systematic Review and Meta-Analysis. Hepatology. 2019;70:1119–1133.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Tacke F, Arrese M, et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2019;69(6):2672–2682.
   PubMed Web of Science ®Google Scholar
• Anstee QM, Reeves HL, Kotsiliti E, et al. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16:411–428.
   PubMed Web of Science ®Google Scholar
• Parthasarathy G, Revelo X, Malhi H. Pathogenesis of Nonalcoholic Steatohepatitis: an Overview. Hepatol Commun. 2020;4(4):478–492.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: implications of a Premature Change in Terminology. Hepatology. 2021;73:1194–1198.
   PubMed Web of Science ®Google Scholar
• Lorbeer R, Bayerl C, Auweter S, et al. Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease. J Hypertens. 2017;35(4):737–744.
   PubMed Web of Science ®Google Scholar
• Cai J, Zhang XJ, Li H. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Med Res Rev. 2019;39:328–348.
   PubMed Web of Science ®Google Scholar
• Simons N, Bijnen M, Wouters KAM, et al. The endothelial function biomarker soluble E-selectin is associated with nonalcoholic fatty liver disease. Liver Int. 2020;40:1079–1088.
   PubMed Web of Science ®Google Scholar
• Zhao YC, Zhao GJ, Chen Z, et al. Nonalcoholic Fatty Liver Disease: an Emerging Driver of Hypertension. Hypertension. 2020;75:275–284.
   PubMed Web of Science ®Google Scholar
• Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: the State of the Disease. Gastroenterology. 2020;158(7):1851–1864.
   PubMed Web of Science ®Google Scholar
• Lonardo A, Nascimbeni F, Mantovani A, et al. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68(2):335–352.
   PubMed Web of Science ®Google Scholar
• Maiorino E, Baek SH, Guo F, et al. Discovering the genes mediating the interactions between chronic respiratory diseases in the human interactome. Nat Commun. 2020;11(1):811.
   PubMed Web of Science ®Google Scholar
• Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020;48:D845–d55.
   PubMed Web of Science ®Google Scholar
• Davis AP, Grondin CJ, Johnson RJ, et al. The Comparative Toxicogenomics Database: update 2019. Nucleic Acids Res. 2019;47(D1):D948–d54.
   PubMed Web of Science ®Google Scholar
• Wang T, Chen B, Meng T, et al. Identification and immunoprofiling of key prognostic genes in the tumor microenvironment of hepatocellular carcinoma. Bioengineered. 2021;12(1):1555–1575.
   PubMed Web of Science ®Google Scholar
• Cheng F, Desai RJ, Handy DE, et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun. 2018;9:2691.
   PubMed Web of Science ®Google Scholar
• Kim KJ, Moon SJ, Park KS, et al. Network-based modeling of drug effects on disease module in systemic sclerosis. Sci Rep. 2020;10:13393.
   PubMed Web of Science ®Google Scholar
• Ghiassian SD, Menche J, Barabási AL. A DIseAse MOdule Detection (DIAMOnD) algorithm derived from a systematic analysis of connectivity patterns of disease proteins in the human interactome. PLoS Comput Biol. 2015;11:e1004120.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16:284–287.
   PubMed Web of Science ®Google Scholar
• Meng Y, Li C, Liu CX. Immune cell infiltration landscape and immune marker molecular typing in preeclampsia. Bioengineered. 2021;12:540–554.
   PubMed Web of Science ®Google Scholar
• Freshour SL, Kiwala S, Cotto KC, et al. Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res. 2021;49:D1144–d51.
   PubMed Web of Science ®Google Scholar
• Battle A, Brown CD, Engelhardt BE, et al. Genetic effects on gene expression across human tissues. Nature. 2017;550:204–213.
   PubMed Web of Science ®Google Scholar
• Pathan M, Keerthikumar S, Ang CS, et al. FunRich: an open access standalone functional enrichment and interaction network analysis tool. Proteomics. 2015;15:2597–2601.
   PubMed Web of Science ®Google Scholar
• Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic Steatohepatitis: a Review. Jama. 2020;323(12):1175–1183.
   PubMed Web of Science ®Google Scholar
• Wu S, Wu F, Ding Y, et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep. 2016;6(1):33386.
   PubMed Web of Science ®Google Scholar
• Fallo F, Dalla Pozza A, Sonino N, et al. Nonalcoholic fatty liver disease, adiponectin and insulin resistance in dipper and nondipper essential hypertensive patients. J Hypertens. 2008;26(11):2191–2197.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
   PubMed Web of Science ®Google Scholar
• Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13:643–54.e1-9.
   Web of Science ®Google Scholar
• Tsuneto A, Hida A, Sera N, et al. Fatty liver incidence and predictive variables. Hypertens Res. 2010;33(6):638–643.
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhang C, Zhang Y, et al. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study. Atherosclerosis. 2015;240(1):144–148.
   PubMed Web of Science ®Google Scholar
• Aneni EC, Oni ET, Martin SS, et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens. 2015;33(6):1207–1214.
   PubMed Web of Science ®Google Scholar
• Petta S, Di Marco V, Pipitone RM, et al. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: genetic and metabolic risk factors in a general population. Liver Int. 2018;38(11):2060–2068.
   PubMed Web of Science ®Google Scholar
• Han J, Wang Y, Yuan Z, et al. Nonalcoholic fatty liver disease represents a greater metabolic burden in patients with atherosclerosis: a cross-sectional study. Medicine (Baltimore). 2019;98(11):e14896.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Younossi Y, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020;69(3):564–568.
   PubMed Web of Science ®Google Scholar
• Wu SJ, Zou H, Zhu GQ, et al. Increased levels of systolic blood pressure within the normal range are associated with significantly elevated risks of nonalcoholic fatty liver disease. Medicine (Baltimore). 2015;94:e842.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zeng Y, Lin C, et al. Hypertension and non-alcoholic fatty liver disease proven by transient elastography. Hepatol Res. 2016;46(13):1304–1310.
   PubMed Web of Science ®Google Scholar
• Gawrieh S, Wilson LA, Cummings OW, et al. Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. Am J Gastroenterol. 2019;114(10):1626–1635.
   PubMed Web of Science ®Google Scholar
• Johnston MP, Patel J, Byrne CD. Multi-drug approaches to NASH: what’s in the development pipeline? Expert Opin Investig Drugs. 2020;29(2):143–150.
   PubMed Web of Science ®Google Scholar
• Sorrentino P, Terracciano L, D’Angelo S, et al. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am J Gastroenterol. 2010;105(2):336–344.
   PubMed Web of Science ®Google Scholar
• Labenz C, Huber Y, Kalliga E, et al. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. Aliment Pharmacol Ther. 2018;48(10):1109–1116.
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Chan WK, Piyachaturawat P, et al. Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study. BMC Gastroenterol. 2020;20(1):88.
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer JR, Li L, et al. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology. 2020;71(3):808–819.
   PubMed Web of Science ®Google Scholar
• German MN, Lutz MK, Pickhardt PJ, et al. Statin Use is Protective Against Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: a Case-control Study. J Clin Gastroenterol. 2020;54(8):733–740.
   PubMed Web of Science ®Google Scholar
• Lau K, Lorbeer R, Haring R, et al. The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study. J Hypertens. 2010;28(9):1829–1835.
   PubMed Web of Science ®Google Scholar
• Sung KC, Wild SH, Byrne CD. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. J Hepatol. 2014;60:1040–1045.
   PubMed Web of Science ®Google Scholar
• Ryoo JH, Suh YJ, Shin HC, et al. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol. 2014;29:1926–1931.
   PubMed Web of Science ®Google Scholar
• Huh JH, Ahn SV, Koh SB, et al. A Prospective Study of Fatty Liver Index and Incident Hypertension: the KoGES-ARIRANG Study. PLoS One. 2015;10:e0143560.
   PubMed Web of Science ®Google Scholar
• Zhou K, Cen J. The fatty liver index (FLI) and incident hypertension: a longitudinal study among Chinese population. Lipids Health Dis. 2018;17:214.
   PubMed Web of Science ®Google Scholar
• Brunner KT, Pedley A, Massaro JM, et al. Increasing Liver Fat Is Associated With Incident Cardiovascular Risk Factors. Clin Gastroenterol Hepatol. 2020;18:1884–1886.
   PubMed Web of Science ®Google Scholar
• Roh JH, Park JH, Lee H, et al. A Close Relationship between Non-Alcoholic Fatty Liver Disease Marker and New-Onset Hypertension in Healthy Korean Adults. Korean Circ J. 2020;50:695–705.
   PubMed Web of Science ®Google Scholar
• Ryoo JH, Ham WT, Choi JM, et al. Clinical significance of non-alcoholic fatty liver disease as a risk factor for prehypertension. J Korean Med Sci. 2014;29:973–979.
   PubMed Web of Science ®Google Scholar
• Feng RN, Du SS, Wang C, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol. 2014;20:17932–17940.
   PubMed Web of Science ®Google Scholar
• Long MT, Pedley A, Massaro JM, et al. The Association between Non-Invasive Hepatic Fibrosis Markers and Cardiometabolic Risk Factors in the Framingham Heart Study. PLoS One. 2016;11:e0157517.
   PubMed Web of Science ®Google Scholar
• Ma J, Hwang SJ, Pedley A, et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol. 2017;66:390–397.
   PubMed Web of Science ®Google Scholar
• Liu P, Tang Y, Guo X, et al. Bidirectional association between nonalcoholic fatty liver disease and hypertension from the Dongfeng-Tongji cohort study. J Am Soc Hypertens. 2018;12:660–670.
   PubMed Web of Science ®Google Scholar
• Tosello-Trampont A, Surette FA, Ewald SE, et al. Immunoregulatory Role of NK Cells in Tissue Inflammation and Regeneration. Front Immunol. 2017;8:301.
   PubMed Web of Science ®Google Scholar
• Oates JR, McKell MC, Moreno-Fernandez ME, et al. Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: the Mac Attack. Front Immunol. 2019;10:2893.
   PubMed Web of Science ®Google Scholar
• Endo-Umeda K, Makishima M. Liver X Receptors Regulate Cholesterol Metabolism and Immunity in Hepatic Nonparenchymal Cells. Int J Mol Sci. 2019;20(20):20.
   Web of Science ®Google Scholar
• Weston CJ, Shepherd EL, Claridge LC, et al. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. J Clin Invest. 2015;125:501–520.
   PubMed Web of Science ®Google Scholar
• Gadd VL, Skoien R, Powell EE, et al. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology. 2014;59(4):1393–1405.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhao XC, Cui W, et al. Genetic and Pharmacologic Inhibition of the Chemokine Receptor CXCR2 Prevents Experimental Hypertension and Vascular Dysfunction. Circulation. 2016;134:1353–1368.
   PubMed Web of Science ®Google Scholar
• Liu F, Zhang G, Sheng X, et al. Effects of hereditary moderate high fat diet on metabolic performance and physical endurance capacity in C57BL/6 offspring. Mol Med Rep. 2018;17:4672–4680.
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Kanno K, Ikuta T, et al. Enhancing hepatic fibrosis in spontaneously hypertensive rats fed a choline-deficient diet: a follow-up report on long-term effects of oxidative stress in non-alcoholic fatty liver disease. J Hepatobiliary Pancreat Sci. 2016;23(5):260–269.
   PubMed Web of Science ®Google Scholar
• Lírio LM, Forechi L, Zanardo TC, et al. Chronic fructose intake accelerates non-alcoholic fatty liver disease in the presence of essential hypertension. J Diabetes Complications. 2016;30(1):85–92.
   PubMed Web of Science ®Google Scholar
• Toblli JE, Muñoz MC, Cao G, et al. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring). 2008;16(4):770–776.
   PubMed Web of Science ®Google Scholar
• Sawada Y, Kawaratani H, Kubo T, et al. Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis. Hepatol Res. 2019;49(3):284–295.
   PubMed Web of Science ®Google Scholar
• Ackerman Z, Oron-Herman M, Grozovski M, et al. Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension. 2005;45(5):1012–1018.
   PubMed Web of Science ®Google Scholar
• Lee S, Han D, Kang HG, et al. Intravenous sustained-release nifedipine ameliorates nonalcoholic fatty liver disease by restoring autophagic clearance. Biomaterials. 2019;197:1–11.
   PubMed Web of Science ®Google Scholar
• Sturzeneker MCS, De Noronha L, Olandoski M, et al. Ramipril significantly attenuates the development of non-alcoholic steatohepatitis in hyperlipidaemic rabbits. Am J Cardiovasc Dis. 2019;9:8–17.
   PubMed Web of Science ®Google Scholar
• Bock KW. Modulation of aryl hydrocarbon receptor (AHR) and the NAD(+)-consuming enzyme CD38: searches of therapeutic options for nonalcoholic fatty liver disease (NAFLD). Biochem Pharmacol. 2020;175:113905.
   PubMed Web of Science ®Google Scholar
• Mardinoglu A, Bjornson E, Zhang C, et al. Personal model-assisted identification of NAD(+) and glutathione metabolism as intervention target in NAFLD. Mol Syst Biol. 2017;13:916.
   PubMed Web of Science ®Google Scholar
• Kono H, Asakawa M, Fujii H, et al. Edaravone, a novel free radical scavenger, prevents liver injury and mortality in rats administered endotoxin. J Pharmacol Exp Ther. 2003;307(1):74–82.
   PubMed Web of Science ®Google Scholar
• Eslam M, Sanyal AJ, George J. MAFLD: a Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(1999–2014):e1.
   Google Scholar
• Arendse LB, Danser AHJ, Poglitsch M, et al. Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. Pharmacol Rev. 2019;71(4):539–570.
   PubMed Web of Science ®Google Scholar
• Marcuccilli M, Chonchol M. NAFLD and Chronic Kidney Disease. Int J Mol Sci. 2016;17(4):562.
   PubMed Web of Science ®Google Scholar
• Musso G, Cassader M, Cohney S, et al. Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease. Trends Mol Med. 2015;21:645–662.
   PubMed Web of Science ®Google Scholar
• Osterreicher CH, Taura K, De Minicis S, et al. Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology. 2009;50(3):929–938.
   PubMed Web of Science ®Google Scholar
• Yang M, Ma X, Xuan X, et al. Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System. Front Pharmacol. 2020;11:432.
   PubMed Web of Science ®Google Scholar
• Sansoè G, Aragno M, Wong F. Pathways of hepatic and renal damage through non-classical activation of the renin-angiotensin system in chronic liver disease. Liver Int. 2020;40(1):18–31.
   PubMed Web of Science ®Google Scholar
• Jayasooriya AP, Mathai ML, Walker LL, et al. Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proc Natl Acad Sci U S A. 2008;105(18):6531–6536.
   PubMed Web of Science ®Google Scholar
• Tiao MM, Lin YJ, Yu HR, et al. Resveratrol ameliorates maternal and post-weaning high-fat diet-induced nonalcoholic fatty liver disease via renin-angiotensin system. Lipids Health Dis. 2018;17:178.
   PubMed Web of Science ®Google Scholar
• Ito K, Zolfaghari R, Hao L, et al. Inflammation rapidly modulates the expression of ALDH1A1 (RALDH1) and vimentin in the liver and hepatic macrophages of rats in vivo. Nutr Metab (Lond). 2014;11(1):54.
   PubMedGoogle Scholar
• Blaner WS. Vitamin A signaling and homeostasis in obesity, diabetes, and metabolic disorders. Pharmacol Ther. 2019;197:153–178.
   PubMed Web of Science ®Google Scholar
• Kuwata K, Shibutani M, Hayashi H, et al. Concomitant apoptosis and regeneration of liver cells as a mechanism of liver-tumor promotion by β-naphthoflavone involving TNFα-signaling due to oxidative cellular stress in rats. Toxicology. 2011;283:8–17.
   PubMed Web of Science ®Google Scholar
• Zhong G, Kirkwood J, Won KJ, et al. Characterization of Vitamin A Metabolome in Human Livers With and Without Nonalcoholic Fatty Liver Disease. J Pharmacol Exp Ther. 2019;370:92–103.
   PubMed Web of Science ®Google Scholar
• Yang CK, Wang XK, Liao XW, et al. Aldehyde dehydrogenase 1 (ALDH1) isoform expression and potential clinical implications in hepatocellular carcinoma. PLoS One. 2017;12(8):e0182208.
   PubMed Web of Science ®Google Scholar
• Haenisch M, Treuting PM, Brabb T, et al. Pharmacological inhibition of ALDH1A enzymes suppresses weight gain in a mouse model of diet-induced obesity. Obes Res Clin Pract. 2018;12(1):93–101.
   PubMed Web of Science ®Google Scholar
• Ziouzenkova O, Orasanu G, Sharlach M, et al. Retinaldehyde represses adipogenesis and diet-induced obesity. Nat Med. 2007;13(6):695–702.
   PubMed Web of Science ®Google Scholar
• Saeed A, Dullaart RPF, Schreuder T, et al. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients. 2017;10(1):10.
   PubMed Web of Science ®Google Scholar
• Makia NL, Bojang P, Falkner KC, et al. Murine hepatic aldehyde dehydrogenase 1a1 is a major contributor to oxidation of aldehydes formed by lipid peroxidation. Chem Biol Interact. 2011;191:278–287.
   PubMed Web of Science ®Google Scholar